News | May 01, 2024
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
2024 full-year revenue guidance raised by US$ 2 billion
2024 full-year revenue guidance raised by US$ 2 billion
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
Alopecia areata usually presents as a few small bald patches in the head
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)